Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight key findings from the publication, such as 'Canagliflozin significantly reduced major cardiovascular events and kidney failure in T2DM and CKD patients,' emphasizing the drug's transformative potential. The frequent use of phrases like 'game changer' and 'critical findings' captures a sense of urgency and significance, contributing to the overall positive tone and agreement among participants about the article's impact.
The majority of discussions reflect strong support for the findings of the publication, particularly regarding the effectiveness of canagliflozin.
Participants express high interest in the implications of the research, indicating its relevance in the medical community.
Many discussions delve into specific data and implications from the study, showcasing a comprehensive understanding of the research.
Users perceive the results as having significant influence on treatment protocols for type 2 diabetes and chronic kidney disease.
New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA2019 https://t.co/pCRJob6LPz @VladoPerkovic @jardine_meg @brendonneuen https://t.co/iYZm5iiHRx
#EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2DM & CKD, including pts who did not have prior CV disease. Read more: https://t.co/MFATs53LZg #AHAJournals https://t.co/Um2vXHeok4
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/47l4nzbDx9
#Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease
https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with T2D and chronic kidney disease, including in participants who did not have prior CVD. #CREDENCE #kidneyInCVD @AHAScience @nephJC https://t.co/wLXOr0DCzJ
【CREDENCE追加解析/ Circ】 CKD合併２型DM4401例ランダム化：SGLT2阻害薬追加で、プラセボに比べ、CV１次予防 [2181例]、２次予防 [2220例] とも、CV死亡・MI・脳卒中リスクは有意に低。HRはそれぞれ0.68と0.85。交互作用p=0.25。 https://t.co/aPumfmUViW https://t.co/gnm8VO9w6k
Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. This video discusses the effectiveness of canagliflozin in significantly reducing major cardiovascular events and…
This episode highlights recent cardiology updates from leading journals. We discuss critical articles, including findings on canagliflozin's impact on cardiovascular events and kidney outcomes in patients with type 2…
RT @cardiomet_CE: 23) At #AHA22, Prof Sattar contextualized new data into prior findings to address a reinforced role for #SGLT2i therapy i…
RT @cardiomet_CE: 23) At #AHA22, Prof Sattar contextualized new data into prior findings to address a reinforced role for #SGLT2i therapy i…
23) At #AHA22, Prof Sattar contextualized new data into prior findings to address a reinforced role for #SGLT2i therapy in persons with #CKD, with or without #T2D. #CREDENCE had addressed ⬆️#albuminuria in G2-G3b CKD (
23) At #AHA22, Prof Sattar contextualized new data into prior findings to address a reinforced role for #SGLT2i therapy in persons with #CKD, with or without #T2D. #CREDENCE had addressed ⬆️#albuminuria in G2-G3b CKD (
この文献、へえー1次予防も効果あるんかなと思ったけど、2型糖尿病＋慢性腎臓病で過去に心血管疾患歴の無い人ってリアルワールドにどのくらいいるのかしら…。と考えたら眠くなってきた。 カナグルが2型糖尿病合併症CKDへ承認きっかけのCREDENCE試験のサブ解析かな https://t.co/idvqHxV12B
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus an... https://t.co/Ek3NKaAAHl #ubc #nephrology
Open Access UCL Research: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial - UCL Discovery https://t.co/yDGnvlzN3H
RT @RevistaMFSamfyc: Canagliflozina y resultados cardiovasculares y renales en la diabetes mellitus tipo 2 y en la enfermedad renal crónica…
Canagliflozina y resultados cardiovasculares y renales en la diabetes mellitus tipo 2 y en la enfermedad renal crónica en grupos de prevención cardiovascular primaria y secundaria https://t.co/QTicnrC4Er PMID 31291786
RT @CircAHA: New #CircOnTheRun podcast episode with corresponding author Dr. Kenneth Mahaffey and associate editor Dr. Naveed Sattar on Can…
RT @CircAHA: New #CircOnTheRun podcast episode with corresponding author Dr. Kenneth Mahaffey and associate editor Dr. Naveed Sattar on Can…
(Circulation) Canagliflozina y resultados cardiovasculares y renales en diabetes mellitus tipo 2 y enfermedad renal crónica en grupos de prevención cardiovascular primaria y secundaria. Resultados del ensayo aleatorizado CREDENCE https://t.co/nKwFqzKCtl https://t.co/Zf4Si9sJku
New #CircOnTheRun podcast episode with corresponding author Dr. Kenneth Mahaffey and associate editor Dr. Naveed Sattar on Canagliflozin and Primary Prevention in T2DM https://t.co/MFTV5nt4Jp Featured Paper: https://t.co/LBZ4wDVhkd #AHAJournals @TheMahaf https://t.co/iMDjrvDh8k
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @CircAHA: #EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2D…
RT @CircAHA: #EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2D…
RT @CircAHA: #EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2D…
RT @CircAHA: #EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2D…
RT @CircAHA: #EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2D…
#EditorsPick: #CREDENCE - SGLT2 inhibitor canagliflozin significantly reduced major CV events & kidney failure in pts with T2DM & CKD, including pts who did not have prior CV disease. Read more: https://t.co/MFATs53LZg #AHAJournals https://t.co/Um2vXHeok4
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @mbotana: Ya en versión papel - Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disea…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @kamleshkhunti: Canagliflozin significantly reduced major cardiovascular events & kidney failure in in T2DM & renal disease -including p…
RT @GotesJose: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Se…
RT @mbotana: Ya en versión papel - Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disea…
RT @mbotana: Ya en versión papel - Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disea…
RT @GotesJose: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Se…
RT @GotesJose: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Se…
RT @GotesJose: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Se…
RT @GotesJose: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Se…
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups | Circulation https://t.co/CwMVUr79mI @MedscapeES @MD_Impacto
Ya en versión papel - Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups | Circulation https://t.co/jFD12MLg5d
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
Found in Circulation, p. CIRCULATIONAHA.119.042007. doi: 10.1161/CIRCULATIONAHA.119.042007.
The trial keeps giving.... Mahaffey, K. W. et al. (2019) ‘Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial’,
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/buwVi5yipt
#Canagliflozin significantly reduced major #CV events, as well as kidney failure, in patients with #T2D & #CKD, including in participants who did not have prior #CVdisease. More in @CircAHA --> https://t.co/zZq0SCHjfm
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
RT @ValleAlfonso: #Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic…
#Canagliflozin significantly ⤵️ major CV events, as well as kidney failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @DanielJDrucker: Primary vs. Secondary Prevention from the CREDENCE Trial | @CircAHA https://t.co/ooOZdZMlqO
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
RT @georgeinstitute: New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA…
New analyses from @georgeinstitute #CREDENCE trial reveal further benefits for #CVD including primary protection. #ADA2019 https://t.co/pCRJob6LPz @VladoPerkovic @jardine_meg @brendonneuen https://t.co/iYZm5iiHRx
RT @DanielJDrucker: Primary vs. Secondary Prevention from the CREDENCE Trial | @CircAHA https://t.co/ooOZdZMlqO
Primary vs. Secondary Prevention from the CREDENCE Trial | @CircAHA https://t.co/ooOZdZMlqO
#Canagliflozin and #Cardiovascular and #Renal Outcomes in Type 2 #Diabetes and Chronic #Kidney Disease in Primary and Secondary #Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/JLMEx58OzK
In CREDENCE, 4401 participants with #T2D & #CKD were randomly assigned to #canagliflozin or placebo on a background of optimized standard of care. The manuscript is now available online. https://t.co/zZq0SCHjfm
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
RT @KidneyInCVD: https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with…
https://t.co/B3ckn3BjwA Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with T2D and chronic kidney disease, including in participants who did not have prior CVD. #CREDENCE #kidneyInCVD @AHAScience @nephJC https://t.co/wLXOr0DCzJ
RT @drdargaray: https://t.co/7AyNFrwAYE @AntonioJordanR @Blanchoblanchet @ESC_Journals @onco_cardiology @endo_german @IncichR @carlos_sierr…
RT @drdargaray: https://t.co/7AyNFrwAYE @AntonioJordanR @Blanchoblanchet @ESC_Journals @onco_cardiology @endo_german @IncichR @carlos_sierr…
https://t.co/7AyNFrwAYE @AntonioJordanR @Blanchoblanchet @ESC_Journals @onco_cardiology @endo_german @IncichR @carlos_sierra @krychtiukmd @neuroecheverria @Dany9_RD @smexcardiologia @cardiodata
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
Credence. Canagliflozina y beneficio cardiovascular y renal https://t.co/UZEa1yYHVc
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/hgNNHG0NpE … https://t.co/t2uCSw2c5h https://t.co/ktr3hP46tZ
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
【CREDENCE追加解析/ Circ】 CKD合併２型DM4401例ランダム化：SGLT2阻害薬追加で、プラセボに比べ、CV１次予防 [2181例]、２次予防 [2220例] とも、CV死亡・MI・脳卒中リスクは有意に低。HRはそれぞれ0.68と0.85。交互作用p=0.25。 https://t.co/aPumfmUViW https://t.co/gnm8VO9w6k
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @rincondesisifo: (Circulation) Versión para cardiólogos del estudio #CREDENCE https://t.co/oic6QeVErr #DM2 Y así lo vimos nosotros ht…
More data..primary prevention of CVD..Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial| @CircAHA https://t.co/Cdi5ze0x7u
Canagliflozin significantly reduced major cardiovascular events, as well as kidney failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease. https://t.co/zCQ5ZAFtTs
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
RT @mbotana: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Car…
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/47l4nzbDx9
RT @FormigaFrancesc: Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secon…
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation https://t.co/oCqipuRdz5
RT @rincondesisifo: (Circulation) Versión para cardiólogos del estudio #CREDENCE https://t.co/oic6QeVErr #DM2 Y así lo vimos nosotros ht…
RT @rincondesisifo: (Circulation) Versión para cardiólogos del estudio #CREDENCE https://t.co/oic6QeVErr #DM2 Y así lo vimos nosotros ht…
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial - https://t.co/a2SDt0i85e
TH
C
MB
AV
KD
宇T
AM
PF
CM
CC
た
UN
UD
AM
RM
C日
SG
S
SO
SE
H
DL
飴
RG
TH
KT
DN
RV
RN
JO
S
JE
PE
D
PH
AT
DP
MK
CH
JL
MV
J
BD
LH
MI
JP
LB
JS
ST
AG
SR
DS
LG
MT
RG
SN
LR
SE
C
I
K
YY
MC
EV
DA
FP
WN
IE
IN
DE
DD
LU
M
JR
TP
DC
CF
KJ
AE
AJ
DM
C
CG
FE
JA
JY
AJ
F
EG
RP
TF
ND
G
RR
FF
H
D